Related by context. All words. (Click for frequent words.) 70 lopinavir r arm 69 Engerix B 68 mg ustekinumab 68 mcg doses 68 prednisone prednisolone plus 68 oxycodone CR 68 8mg/kg 67 mcg albinterferon alfa 2b 67 budesonide pMDI 67 HBeAg negative patients 67 infliximab monotherapy 67 mcg QD 67 PREZISTA ritonavir 67 linaclotide treated 67 #mg q8h 66 placebo dexamethasone 66 REYATAZ r arm 66 plus OBT 66 4mg/kg 66 PREZISTA r arm 66 achieved ACR# 66 ACR# ACR# 66 ug dose 66 mg BID dose 66 microgram kg 66 mg TID 66 salmeterol fluticasone propionate 65 oxycodone IR 65 adjunctive placebo 65 mg simvastatin 65 mg QD 65 relapsed MM 65 mcg BID 65 REMICADE monotherapy 65 mcg kg REBETOL 65 comparator arm 65 ug kg 65 plus dexamethasone 65 -#.# log# copies mL 65 unfractionated heparin UFH 65 placebo PBO 65 % CI #.#-#.# [003] 65 mg Androxal 65 mcg Albuferon 64 nonsignificant difference 64 ritonavir boosted atazanavir 64 mg eq 64 efavirenz EFV 64 FluCAM arm 64 3mg/kg 64 certolizumab 64 μg dose 64 ACTEMRA TM 64 adjunctive ABILIFY 64 mg q#h 64 FOLFOX4 alone 64 receiving INTRON 64 EURIDIS 64 FOLFIRI alone 64 mg BID 64 daily Infergen 63 CANCIDAS 63 amoxicillin clavulanate 63 lopinavir r 63 generalized edema 63 Double Blind Randomized 63 ng dL 63 biologic DMARD 63 peginterferon alfa 2a Pegasys 63 metastatic GIST 63 saline placebo 63 ARCOXIA 63 abdominal pain abdominal discomfort 63 % CI #.#-#.# [007] 63 5-FU/LV 63 LEXIVA r 63 adverse reactions occurring 63 mg Lucentis 63 Median PFS 63 R adefovir dipivoxil 63 IIIa inhibitors 63 % Confidence Interval 63 nadroparin 63 salmeterol fluticasone 63 pegylated interferon alfa 2b 63 Acetate Rectal Suppositories 63 atazanavir ritonavir 63 abacavir lamivudine 63 rectal tenesmus 63 Mg Uk 62 treatment naive genotype 62 #mg BID [001] 62 epoetin alpha 62 Hycamtin ® 62 treatment naïve genotype 62 #mg/day [001] 62 â ‰ ¥ 62 pooled comparator 62 dapagliflozin plus 62 titrated glipizide 62 CHAMPION PCI 62 #mg/m# [001] 62 glulisine 62 receiving PEGINTRON 62 Pred Forte 62 receiving golimumab 62 mCi m 2 62 beta2 agonist 62 TEAEs 62 HBeAg positive patients 62 ® emtricitabine 62 #mg BID [003] 62 rFSH 62 insulin glulisine 62 mg subcutaneous 62 cGy 62 mg dosed twice 62 TPV r 62 rizatriptan 62 ARIXTRA 62 definite stent thrombosis 62 Oral Fingolimod 62 #-#,# mg 62 BMS p = 62 plus prednisone 62 peginterferon alfa 2b 62 Januvia ® 62 BENICAR HCT 62 octreotide LAR 62 TAXUS p value 61 Hepatitis C Antiviral 61 -#.# mg dL [002] 61 KRAS mutations occur 61 Randomized Double Blind 61 somatostatin analog 61 q#h 61 Peginterferon Alfa 2a 61 #.#mg/dL 61 5mg/kg 61 MMX mesalamine 61 partial remissions 61 sirolimus stent 61 vincristine doxorubicin 61 #.#/#.# mmHg [001] 61 splenectomized 61 discontinuations due 61 fatigue asthenia 61 TLUS 61 severe exacerbations 61 multicenter randomized controlled 61 arterial thromboembolic events 61 PREZISTA r 61 corticosteroid dose 61 ARCALYST ® 61 ALT elevation 61 nasopharyngitis 61 MCyR 61 #mg #mg #mg [003] 61 Folfox 61 mg kg dose 61 alfa 2a 61 ULORIC 61 atorvastatin #mg 61 BARACLUDE ® 61 inhalations twice 61 diarrhea nausea fatigue 61 mITT population 61 blinded randomized placebo controlled 61 BENCHMRK 61 x ULN 61 HBeAg + 61 heFH 61 FOLFOX4 61 tacrolimus ointment 61 -#.# log# 61 mL/min/#.# m2 61 clodronate 61 ng dl 61 mg administered orally 61 mg RDEA# 61 stage IIIb IV 61 Flu Cy 61 tolterodine ER 61 mg qd 61 melphalan prednisone 61 daily subcutaneous injections 61 Kidney Int 61 plus prednisone prednisolone 61 Primary endpoints 61 receiving highly emetogenic 61 plus methotrexate 61 VELCADE melphalan 61 aged ≥ 60 Viread Emtriva 60 mean baseline A1C 60 oral allopurinol 60 ARIXTRA R 60 intravenous bolus 60 Telithromycin 60 deep venous thromboses 60 ritonavir boosted 60 Contrave# 60 BENICAR 60 Pegasys peginterferon alfa 2a 60 postmenopausal osteoporotic women 60 #μg [001] 60 chlorambucil 60 PEGINTRON TM 60 lopinavir ritonavir Kaletra 60 FDA defined valvulopathy 60 tapentadol ER 60 ATACAND 60 tipranavir r 60 1mg 2mg 60 Randomized Phase II 60 #mg QD [002] 60 telaprevir pegylated interferon 60 NSABP B 60 fluoxetine paroxetine 60 CALERIE 60 tenofovir emtricitabine 60 naïve HCV 60 5 Fluorouracil 60 evaluable subjects 60 medroxyprogesterone acetate 60 insulin detemir 60 golimumab CNTO 60 sham injections 60 BUPHENYL R sodium phenylbutyrate 60 using lactulose concomitantly 60 lamivudine monotherapy 60 placebo p = 60 subcutaneously administered 60 Androgel R 60 Mg Usa 60 log# copies mL 60 mg Proellex 60 Study Evaluating 60 Lupuzor ™ 60 CI #.#-#.# [002] 60 Suppl. 60 tapentadol IR 60 Peg IFN 60 cisplatin gemcitabine 60 ACR# response 60 concurrent ITP 60 receiving ISENTRESS 60 confidence interval #.#-#.# 60 dalteparin 60 ONGLYZA saxagliptin 60 squamous histology 60 COMBIVIR 60 simvastatin #mg 60 PROCTOCORT R 60 aminotransferase elevations greater 60 ertapenem 60 BUPHENYL 60 Myocardial Infarction Study 60 vilanterol 60 evaluating Actimmune 60 microg 60 #ug [001] 60 Index CDAI 60 emtricitabine tenofovir 60 mg tenofovir disoproxil fumarate 60 mg d 60 low dose Iluvien 60 humanized interleukin 6 60 mcg dose 60 5mg #mg 60 CIMZIA TM 60 plus glycoprotein IIb 60 mg p = 60 #mg/m# [002] 60 Relapsing Multiple Sclerosis 60 adefovir treated 60 mg dose 60 severe neutropenia 60 J Natl Cancer Inst 60 XIENCE V PROMUS Stent 60 receiving VICTRELIS 60 desvenlafaxine succinate 60 Adjunctive Therapy 60 Apidra ® 60 methotrexate monotherapy 60 RGT arm 60 HBeAg seroconversion 60 oral ribavirin 60 mcg kg 60 Pooled Analysis 60 pimecrolimus cream 60 FOLPI 60 NATRECOR R 60 TMC# C# 60 interferon gamma 1b 60 cells uL 60 Peginterferon 60 VIRAMUNE XR 60 Hydrochlorothiazide Tablets 60 venlafaxine XR 60 CK # plasma concentrations 60 PROCTOCORT ® Suppository Hydrocortisone 60 mild renal insufficiency 60 azilsartan medoxomil 60 Secondary efficacy endpoints 60 pegylated interferon alpha 59 plus COPEGUS 59 oral rivaroxaban 59 achieved sustained virologic 59 microbiologically evaluable 59 achieved sustained virological 59 mometasone furoate 59 undetectable HBV DNA 59 plus aztreonam 59 divalproex sodium 59 oral hypoglycemic agent 59 pegylated alpha interferon 59 mg m² 59 FOLFOX 59 log# IU mL 59 tipranavir ritonavir 59 fluticasone salmeterol 59 imipenem 59 HBeAg positive 59 patients evaluable 59 q8h 59 interferon alfa 2a 59 zidovudine lamivudine 59 baseline A1C 59 oral diclofenac 59 piperacillin tazobactam 59 Prolongs Survival 59 #.#g/day 59 receiving prophylactic anticoagulation 59 SSRI SNRI 59 ascending dose 59 Platinol ® 59 Interferon alfa 59 doxazosin 59 RLAI 59 bortezomib refractory 59 REYATAZ r 59 pmol L 59 μg kg 59 Viread Emtriva SUSTIVA 59 neuropathy sensory 59 CR CRu 59 Losartan Potassium 59 kilogram mg kg 59 Posaconazole 59 azathioprine monotherapy 59 FOLFIRI 59 mitoxantrone plus 59 COZAAR 59 Newly Diagnosed Patients 59 PEG interferon 59 TMC# r 59 biochemical relapse 59 CIMZIA TM certolizumab pegol 59 lispro 59 alfuzosin 59 doxorubicin cyclophosphamide 59 non valvular atrial 59 Betaferon R 59 mCi kg 59 mg/m2/day 59 tenofovir FTC 59 Rate ORR 59 See CLINICAL PHARMACOLOGY 59 nadolol 59 nucleoside naive 59 RAPTIVA 59 QTcF 59 TDF FTC 59 spud #-#-# drlg [003] 59 rimonabant #mg 59 #/#.# mcg 59 HUMIRA achieved PASI 59 #mg/#mg 59 oral vancomycin 59 ibandronate 59 plus gemcitabine 59 pegylated interferon alpha 2a 59 PEGASYS ® 59 zonisamide SR 59 recurrent glioblastoma multiforme 59 nasopharyngitis upper 59 myocardial infarction ventricular fibrillation 59 μg d 59 anastrazole 59 Carotid Revascularization Endarterectomy vs. 59 seroconverted 59 del 5q MDS 59 p = NS 58 tazobactam 58 Infusion Reactions Severe 58 irbesartan 58 aspirin clopidogrel 58 galiximab 58 baseline HbA1c 58 HAM D# scores 58 QD dosing 58 pharyngolaryngeal pain 58 colorectal adenoma 58 carboplatin paclitaxel 58 leukopenia 58 mg/# hours 58 mcg 58 Kaplan Meier estimates 58 zolmitriptan 58 ® fluocinonide Cream 58 sevelamer hydrochloride 58 ug mL 58 Indacaterol 58 μg L 58 -#.# mg dL [001] 58 baseline FEV 58 + PH# 58 recurrent venous thromboembolism 58 Am J Cardiol 58 ACR Pedi 58 CRp 58 elevated ALT 58 migalastat HCl 58 DAS# remission 58 dacarbazine DTIC 58 #/#mg 58 % mlink 58 Arch Intern Med 58 Paraplatin ® 58 mEq L 58 dose melphalan 58 gemcitabine cisplatin 58 conjugated equine estrogens 58 subcutaneous dose 58 achieved statistical significance 58 AVONEX ® 58 FluCAM 58 Initiated Phase 58 #mg/day [002] 58 non splenectomized 58 Nebulized 58 IFN α 58 Operative mortality 58 YERVOY 58 MAGE A3 ASCI 58 dizziness nausea diarrhea 58 cEVR 58 severe NCI Grades 58 cyclophosphamide methotrexate 58 ISTODAX ® 58 receiving Vectibix monotherapy 58 underwent percutaneous coronary 58 lumbar spine BMD 58 Elitek 58 candesartan cilexetil 58 #mg/kg [002] 58 FIRMAGON 58 hypophosphatemia 58 cytogenetic response 58 underwent CABG 58 Lantus ® 58 ALT flares 58 administered cetrorelix 58 μg mL 58 highly emetogenic 58 Beclomethasone 58 splenectomized patients 58 APTIVUS r 58 #mg doses [002] 58 peginterferon alfa 2a #KD 58 anemia hemoglobin 58 Xatral R 58 binary restenosis 58 Tiotropium 58 low dose cytarabine 58 underwent surgical resection 58 VaD 58 dacarbazine chemotherapy 58 Pemetrexed 58 TAXUS ATLAS 58 6mg 58 SCIg 58 Hazard Ratio 58 mg kg Hematide 58 MBq 58 Perforomist Inhalation Solution 58 quetiapine risperidone 58 assessing T DM1 58 prucalopride 58 SGPT 58 ZACTIMA 58 http:/events.fai.org 58 dosing cohort 58 imiquimod cream 58 Eur Arch 58 Single Dose 58 achieved PASI 58 mg orally 58 randomized #:# 58 achieved CCyR 58 cells mcL 58 Infusion reactions 58 NovoLog ® Mix 58 IV bolus 58 PRECiSE 58 achieved mucosal healing 58 PEG IFN 58 mIU mL 58 elevated transaminases 58 topical gel formulation 58 events AEs 58 REYATAZ ritonavir 58 J Foot Ankle 58 n = 58 pegylated interferon alfa 2a 58 Teriflunomide 58 angioneurotic edema 58 Pharmacokinetics PK 58 MoxDuo TM IR 58 bepotastine besilate nasal spray 58 LOVENOX 58 Zometa hazard 58 CLL SLL 58 Timed Walk 58 neutropenia dehydration dyspnea 58 sUA 58 Pegasys ® 58 XIENCE V vs. 58 irinotecan cisplatin 58 proctitis 58 dosing cohorts 58 Controlled Trial 58 lymphocytosis 58 IFN alfa 58 adverse reactions ≥ 58 Brief Psychiatric 58 doripenem 58 diarrhea nausea abdominal pain 58 nitroprusside 58 alpha 2a 58 cilostazol 58 primary hypercholesterolemia 58 J Clin Oncol 58 iniparib BSI 58 aldosterone antagonist 58 Relapsing Remitting Multiple Sclerosis 58 beclomethasone dipropionate 58 refractory NSCLC 58 suppl. 57 PegIFN 57 VICTOR E1 57 MACUGEN 57 #mg dose [003] 57 subcutaneous doses 57 pmol liter 57 fluticasone furoate 57 goserelin 57 CI #.#-#.# [001] 57 Benazepril 57 plus GP IIb 57 REYATAZ ® 57 Psychiatry Clin Neurosci 57 BZA CE 57 pyrexia mucositis sepsis febrile 57 CIMZIA ™ 57 DAS# CRP 57 EDARBI 57 CALGB # [002] 57 μg doses 57 mU liter 57 NIH CPSI 57 active comparator 57 treatment naļve 57 essential thrombocythemia ET 57 stage IIIb 57 antiretroviral naïve 57 #mg ATC 57 ALGRX 57 ceftriaxone 57 endoscopic remission 57 brand ciclesonide HFA 57 Hormone Refractory Prostate Cancer 57 myelodysplastic myeloproliferative diseases 57 intravenous REOLYSIN 57 CsA 57 #ug [002] 57 metformin XR 57 TAXOTERE R 57 HYZAAR 57 CR nPR 57 GOUT 57 High Dose quadruples 57 mcg mL 57 sirolimus eluting stent 57 mg/m2 dose 57 Val HeFT 57 PEG Intron 57 flutamide 57 Lucentis monotherapy 57 prospectively stratified 57 HCV RESPOND 2 57 inhaled corticosteroid ICS 57 kBq kg 57 valsartan Diovan 57 headache abdominal pain 57 salmeterol inhalation powder 57 Randomized Evaluation 57 argatroban 57 dimeglumine 57 recurrent VTE 57 Lupuzor TM 57 symptomatic BPH 57 Non inferiority 57 stage IIIB 57 febrile neutropenia 57 moderately emetogenic 57 plus medroxyprogesterone acetate 57 & s2 = 57 INSPIRE Trial Phase III 57 ATV RTV 57 ACE Inhibitors 57 HCV SPRINT 57 azilsartan medoxomil plus 57 hours postdose 57 zoledronic acid Reclast 57 Nystatin 57 #-# Full Text 57 null responder HCV 57 Multicenter Automatic Defibrillator Implantation 57 metformin sulfonylurea 57 XIENCE V demonstrated 57 Ozarelix 57 Ann Oncol 57 herpetic keratitis 57 Lopressor 57 Desvenlafaxine Succinate 57 ORENCIA ® 57 TYGACIL 57 #mg dosing group 57 intramuscular dose 57 histologically confirmed 57 Cancer Incidence Mortality 57 Copegus ribavirin 57 #mg ritonavir 57 #.#mg/kg [002] 57 mg subcutaneously 57 PSA nadir 57 CYPHER Stent 57 balsalazide disodium Capsules 57 micafungin 57 mg kg hr 57 rosuvastatin Crestor 57 unresectable stage 57 inhaled budesonide 57 Adjusted EBITDAR margin 57 GERD symptom 57 IIIa inhibitor 57 Keppra R 57 Sanofi Pasteur Fluzone 57 Prostate Cancer Prevention 57 dasatinib Sprycel ® 57 idraparinux 57 mg hydrochlorothiazide 57 abacavir Ziagen 57 P = .# 57 #.#/#.# mmHg [002] 57 hepatitis C genotype 57 glipizide plus 57 hypogonadal men 57 IXEMPRA 57 Epoetin Alfa 57 Arch Neurol 57 microbiological eradication 57 Is Well Tolerated 57 % CI #.#-#.# [006] 57 HCV Genotype 57 PREMPRO 57 DEB# 57 recurrent genital herpes 57 GAMMAGARD 57 incidence ≥ 57 trivalent inactivated vaccine 57 pT3 57 Lymphocytic 57 mmHg diastolic 57 Fluticasone Propionate 57 Submitted Pursuant 57 R# #mg BID 57 benazepril 57 p = #.# [003] 57 Omigard TM omiganan pentahydrochloride 57 Randomized Study 57 PENTASA 57 DOXIL 57 RECORD1 57 CorVue ™ 57 Q2W 57 events SAEs 57 mg/# mg [002] 57 placebo fluoxetine 57 pharmacologically active isomer 57 MGd 57 TRELSTAR ® 57 CD3 + 57 budesonide formoterol 57 nondiabetic patients 57 Aptivus ® 57 ethambutol 57 registrational Phase 57 timolol maleate 57 leucopenia 57 LAB CGRP 57 RE LY ® 57 intravenous RSD# 57 Median progression 57 mIU ml 57 carboplatin AUC 57 Community Acquired Pneumonia 57 serum IGF 57 peginterferon alfa 2a 57 CHANGE WEEKLY CHANGE 57 GLIADEL Wafer 57 % CI #.#-#.# [008] 57 DAS# scores 57 Castration Resistant Prostate Cancer 57 Forodesine HCl 57 ANN INTERN MED 57 PRADAXA #mg 57 Treatment Naive Patients 57 DAPT 57 EBMT criteria 57 telaprevir dosed 57 fluticasone propionate FP 57 adriamycin 57 doxorubicin docetaxel 57 oral prednisolone 57 mg/#.# mg [002] 57 erosive gastritis 57 biphasic insulin aspart 57 hyperphenylalaninemia HPA due 57 mg calcium 56 ribavirin RBV 56 lispro alone 56 ARB telmisartan 56 Meets Primary Endpoint 56 asthenia fatigue 56 Randomized controlled 56 investigational saxagliptin 56 Nephrol Dial Transplant 56 Flovent HFA 56 Partial Response 56 mg/# h 56 calculated creatinine clearance 56 Randomised 56 VARIVAX 56 XOPENEX HFA 56 Randomized Phase 56 fosamprenavir 56 μmol L 56 unresectable HCC 56 oral amoxicillin 56 Psoriasis Area 56 ALVESCO 56 J Am Coll 56 IFL chemotherapy regimen 56 echinacea tablets 56 carbamazepine phenobarbital phenytoin rifampin 56 Non Responders 56 FUSILEV enhances 56 micrograms mcg 56 CATIE AD 56 abdominal pain flatulence 56 Homes Sold tbr 56 ACR# responses 56 intravenous dosing 56 Cytarabine Liposome Injection 56 teriflunomide 56 pegylated liposomal doxorubicin 56 randomized #:#:# 56 adenoma recurrence 56 Lubiprostone 56 risedronate Actonel 56 Degarelix 56 MIC# [001] 56 receiving FUSILEV 56 mL/min/#.# m 2 56 constipation dizziness 56 #μg [002] 56 plus ribavirin 56 Investigational Treatment 56 AIR CF1 56 #mg capsules [001] 56 Tarceva TM 56 Treated Patients 56 fluvastatin 56 Stenting Trial 56 REVIVE Diabetes 56 ethinyl estradiol tablets USP 56 APTIVUS R 56 bone marrow reticulin deposition 56 moderate renal impairment 56 PASI scores 56 myalgia arthralgia 56 fluticasone propionate 56 Raptiva r 56 mso footer margin 56 seroprotective 56 VIIBRYD 56 tumor progression TTP 56 dexamethasone Decadron 56 antiretroviral naive 56 Pegylated Interferon 56 TAXUS Express Stent 56 acute bipolar mania 56 0mg 56 PegIntron 56 nicardipine 56 dose Iluvien 56 Decitabine 56 postintervention 56 Tegretol carbamazepine 56 interferon alfa 2b 56 IEQ kg 56 #.#-#.# [011] 56 mg/# mL [002] 56 Adefovir 56 Hypertensive adverse reactions 56 Fasting blood glucose 56 tamoxifen Nolvadex ® 56 Cream USP 1 56 degarelix 56 peripheral sensory neuropathy 56 bupropion SR 56 Heterozygous Familial Hypercholesterolemia 56 sunitinib malate 56 ritonavir boosted lopinavir 56 intratympanic 56 double blinded randomized 56 Besivance TM 56 fluticasone 56 gadobutrol 56 serum leptin 56 mg/# mg [001] 56 evaluable 56 nodular partial response 56 pruritis 56 mycophenolate mofetil 56 #R #R #R [002] 56 Evoclin R 56 ST Elevation Myocardial 56 buproprion 56 LYSTEDA 56 morphometric vertebral fractures 56 Rating Scale MADRS 56 % asthenia malaise 56 Score TOS 56 CI -#.# 56 CALGB 56 urinary N telopeptide 56 Lamictal XR 56 receiving XGEVA 56 Crohn Disease Activity 56 Randomized Controlled 56 Lovenox enoxaparin sodium 56 Consensus +#.# 56 NCCTG N# 56 mg kg belimumab 56 retinal vein occlusion 56 RECIST Response Evaluation Criteria 56 aspartate aminotransferase 56 EFFEXOR XR 56 baseline PASI 56 seropositive patients 56 micrograms mL 56 fluticasone propionate nasal spray 56 Biaxin R 56 -#.# ± [002] 56 serotonin norepinephrine reuptake inhibitor 56 Bicalutamide 56 mg iv peramivir 56 AVOREN 56 nausea dehydration dyspnea 56 complete cytogenetic response 56 adult chronic ITP 56 rFVIIa 56 Fludara 56 NPH insulin 56 See WARNINGS 56 p = .# [001] 56 boosted protease inhibitor 56 BCIRG 56 mRCC 56 Secondary endpoints include 56 subcutaneous enoxaparin 56 HIV uninfected 56 acarbose 56 CCyR 56 Suppository Hydrocortisone Acetate Rectal 56 Scale EDSS score 56 Solid Tumors criteria 56 baseline Hb 56 aldosterone antagonists 56 Doxil ® 56 ribavirin Copegus 56 Sorafenib HCC Assessment 56 mg dosed once 56 aspirin heparin 56 Suppositories 56 oral antidiabetic medication 56 microalbumin test 56 placebo controlled clinical 56 CLARITY study 56 IMiDs ® compound 56 TRELSTAR R 56 via intradermal injections 56 evaluating tivozanib 56 antiepileptics 56 ADCS CGIC 56 paclitaxel cisplatin 56 Biaxin clarithromycin 56 insulin glargine rDNA origin 56 APTIVUS 56 Mestinon 56 mEq 56 refractory chronic lymphocytic 56 relapsed refractory multiple myeloma 56 stomatitis pharyngitis 56 cefuroxime 56 CDAI score 56 confidence interval CI 56 mg + GLY 56 neutropenia anemia 56 #mg #mg #mg [002] 56 ceftazidime 56 CIMZIA R 56 nevirapine Viramune 56 Fluticasone 56 TNF antagonists 56 mg kg cohorts 56 retrospective cohort 56 log# 56 Havrix 56 ABC/3TC 56 Patients Treated With 56 GlaxoSmithKline Zofran 56 NOXAFIL Oral Suspension 56 tirofiban 56 primary percutaneous coronary 56 angiotensin converting enzyme inhibitor 56 Follicular Lymphoma 56 designated HVTN 56 LPV r 56 drotrecogin alfa activated 56 Prospective Randomized Trial 56 Antiviral Therapy 56 #mg QD [001] 56 forodesine 56 Dermatologic toxicities 56 EQUETRO 56 clinically evaluable patients 56 tinidazole 56 Expanded Disability Status 56 microgram mcg 56 seroprotection 56 pyrimidine nucleoside analog 56 Ishak fibrosis score 56 MIRAPEX 56 Parnate 56 dexamethasone intravitreal implant 56 peginterferon alpha 2a 56 included neutropenia anemia 56 racemic albuterol 56 Bayer HealthCare Onyx Pharmaceuticals 56 transaminase elevations 56 daunorubicin 56 NOAEL 56 YERVOY ipilimumab 56 Pegasys plus Copegus 55 mcg kg min 55 GLIADEL R Wafer 55 mg kg REMICADE 55 alanine aminotransferase ALT 55 GnRH agonist 55 rectal tenesmus #.# 55 #.#mg #mg 55 metronidazole gel 55 Capsules USP 55 9mg 55 STELARA ® 55 euthyroid 55 Acute Coronary Syndromes ACS 55 posaconazole 55 Cutaneous T 55 olanzapine LAI 55 alefacept 55 unfractionated heparin 55 nasopharyngitis headache 55 Improves Outcomes